Changjiang Pharmaceutical Group (300391.SZ): The company's stock may be forcibly delisted due to major violations of the law.

Changjiang Pharmaceutical Group (300391.SZ) announced that on December 26, 2025, it received a "Notice" issued by the China Securities Regulatory Commission. According to the "Notice", it was determined that the annual reports for the years 2021, 2022, and 2023 contained false records. The company overstated operating income by 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan respectively in the annual reports for 2021 to 2023, accounting for 9.12%, 17.57%, and 19.51% of the disclosed operating income for the period; overstated total profits by 56.40 million yuan, 63.37 million yuan, and 43.70 million yuan respectively, accounting for 35.62%, 88.23%, and 6.42% of the total disclosed profits for the period. Additionally, due to the unreasonable recognition of losses for the Changjiang Weichuang Traditional Chinese Medicine City Trading Center project in 2022, the company overstated total profits by 4.55 million yuan in the annual report for 2022, accounting for 6.34% of the total disclosed profits for the period. The company may trigger the "Shenzhen Stock Exchange GEM Stock Listing Rules" article 10.5.2(6), which specifies the circumstances of major illegal compulsory delisting: "The company has disclosed false financial indicators in its annual reports for three consecutive years as stipulated in the administrative penalty decision of the China Securities Regulatory Commission, including operating income, total profits, net profits, assets or liabilities in the balance sheet." The company's stock may face significant illegal compulsory delisting.